Last reviewed · How we verify
NTQ1062+Fulvestrant
NTQ1062 is a selective estrogen receptor degrader (SERD) combined with fulvestrant, an estrogen receptor antagonist, to block estrogen signaling in hormone receptor-positive breast cancer.
NTQ1062 is a selective estrogen receptor degrader (SERD) combined with fulvestrant, an estrogen receptor antagonist, to block estrogen signaling in hormone receptor-positive breast cancer. Used for Hormone receptor-positive, HER2-negative metastatic breast cancer.
At a glance
| Generic name | NTQ1062+Fulvestrant |
|---|---|
| Sponsor | Nanjing Chia-tai Tianqing Pharmaceutical |
| Drug class | Estrogen receptor degrader / Estrogen receptor antagonist combination |
| Target | Estrogen receptor alpha (ERα) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
NTQ1062 functions as a SERD that degrades the estrogen receptor protein, while fulvestrant is a selective estrogen receptor modulator that competitively binds and antagonizes the estrogen receptor. Together, this combination provides dual mechanisms to suppress estrogen receptor-driven proliferation in hormone receptor-positive breast cancer cells, potentially overcoming resistance to standard endocrine therapies.
Approved indications
- Hormone receptor-positive, HER2-negative metastatic breast cancer
Common side effects
- Hot flashes
- Fatigue
- Nausea
- Arthralgia
- Vaginal bleeding
Key clinical trials
- A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer (PHASE3)
- A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NTQ1062+Fulvestrant CI brief — competitive landscape report
- NTQ1062+Fulvestrant updates RSS · CI watch RSS
- Nanjing Chia-tai Tianqing Pharmaceutical portfolio CI